At a glance
The most concerning issue in the current market is: Against the background of high valuation and fragile financial structure, AbbVie (ABBV) can achieve a smooth transition by increasing the volume of new drugs and support its stock price to continue to rise.
Key research points
- Technical long-short game intensifies: The stock price fluctuated in the range of $281.07–$298.74. It recently pulled back to $288.24 and then rebounded to $291.31, showing that short-term buying is still resilient, but the RSI fell from 73.39 to 62.66, and the MACD fell from 7.04 to 6.76, indicating that the upward momentum is weakening.
- There is a conflict between valuation and growth: The current price-to-earnings ratio (TTM) is 50.05, which is significantly higher than the industry average, but the forward-looking P/E ratio is only 17.99, and the PEG ratio is as low as 0.59, reflecting the market's extremely high expectations for earnings growth. If the future growth rate is less than expected, the valuation may face re-rating pressure.
- Aggressive financial structure: Current ratio 0.87 is below 1, shareholders' equity is negative (-$4.583 billion), net debt reaches $70.129 billion, and although free cash flow is strong ($17.693 billion), the health of the balance sheet is questionable.
- The pace of core product substitution is under pressure: After Humira's patent expiration, its market share continues to be eroded by biosimilars. Two similar drugs have been approved in Europe since October 2026, and new drugs such as ABBV-447 are only expected to be ramped up in 2027. There is a risk of a two-year "revenue vacuum period".
Bull case
- The new drug pipeline is making positive progress. ABBV-447 achieved an overall response rate of 78% in phase III clinical trials. If approved, it will bring new growth points and is expected to drive double-digit revenue growth in the next three years.
- Free cash flow has exceeded US$15 billion for several consecutive quarters, supporting the company's dividend and repurchase plans, reflecting its strong cash generation capabilities and providing a funding basis for transformation.
- The forward P/E ratio of 17.99 and PEG of 0.59 indicate that the valuation has not fully reflected the growth potential, and there is room for upward repair if profits are realized.
Get the overnight US stocks & China ADRs brief in your inbox at 08:00 Tokyo time
Free: the condensed daily brief plus a weekly email digest. No pop-ups, no upsell — one-click unsubscribe in every email.
Cautious view
- A current ratio lower than 1 and shareholders' equity is negative indicates that the company's financial structure is highly dependent on external financing and its ability to resist risks is weak. If the interest rate environment deteriorates or cash flow is interrupted, it may trigger a liquidity crisis.
- Humira is facing the impact of biosimilar drugs in the European market. It is expected that revenue will drop by 15%-20% starting from 2027. However, the launch of new drugs lags behind and cannot fill the gap in time. There is a risk of a cliff-like decline in revenue.
- The technical aspect shows that momentum is declining, and the price is approaching the historical high of $298.74. However, the trading volume has not been enlarged simultaneously, and there is a divergence between volume and price. Be wary of signs of major shipments.
Risks
- Policy Risk: The U.S. Inflation Reduction Act allows Medicare to negotiate prices for high-priced drugs, which may compress company profit margins, especially affecting high-value new drugs.
- Competition Risk: The European Union has approved a number of Humira biosimilars, and competition from generic drugs in Asia and emerging markets has intensified, which may accelerate the decline in the market share of core products.
- Financial Risk: Net debt is as high as US$70.129 billion, and the interest coverage ratio is only 5.8 times. If financing costs increase or profits decline, debt repayment pressure will increase significantly.
- R&D Risk: There are uncertainties in the advancement of new drug pipelines, such as the approval progress of ABBV-447 and whether clinical results continue to be better than those of the control group, etc., which may affect commercialization prospects.
- Event Risk: If the next quarter's financial report shows that new drug sales are lower than expected or cash flow fluctuates, it may cause market confidence to shake.
Metrics to watch
- New drug sales data: Focus on the revenue contribution of Skyrizi, Rinvoq and Botox in the fourth quarter of 2026 and the first quarter of 2027 to determine whether they can effectively hedge against the decline of Humira.
- Free Cash Flow Change: Track whether subsequent quarterly free cash flow remains above $15 billion to assess the sustainability of the company's hematopoietic capabilities.
- Changes in institutional holdings: Observe changes in the shareholding ratios of large funds such as Morgan Stanley and BlackRock to identify whether smart money continues to withdraw.
- EU Market Performance: Pay attention to the year-on-year changes in Humira sales in Europe to determine the actual impact of the impact of biosimilar drugs.
- Next financial report release: The financial report released in November 2026 will disclose the latest revenue, profit and guidance, which is a key node to verify the growth logic.